Skip to content

Cancer sponge test could be rolled out across NHS England in 2027

Cancer sponge test could be rolled out across NHS England in 2027

The NHS in England could introduce routine capsule sponge tests for patients with persistent acid reflux under new draft guidance from the National Institute for Health and Care Excellence (NICE). The minimally invasive procedure helps identify Barrett’s oesophagus, a condition associated with an increased risk of oesophageal cancer.

The proposed rollout would allow eligible patients to undergo testing in GP surgeries and community diagnostic centres rather than hospitals. The procedure takes only a few minutes and does not require sedation, potentially reducing demand for conventional endoscopy.

  • NICE recommends cancer sponge tests for patients with persistent reflux and additional risk factors, with final guidance expected in February 2027.
  • The procedure can be completed in under 10 minutes without sedation, potentially reducing hospital endoscopies and improving access to early cancer detection.
  • NHS pharmacy pilots have tested 268 patients, with further expansion planned for January 2027 and a target of 1,360 participants.

More than 9,000 people are diagnosed with oesophageal cancer annually in the UK, while an estimated 1-2% of adults have Barrett’s oesophagus.

The recommendations cover two capsule sponge technologies, Cytosponge and EndoSign. Both collect cells from the oesophageal lining to identify abnormalities that may require further investigation (see about Cancer Health Insurance. What Factors Should You Consider Before Buy Policy?).

How the cancer sponge test detects oesophageal abnormalities

The capsule sponge test, commonly described as a “sponge on a string”, is designed to collect cells from the lining of the oesophagus without using an endoscope.

Patients swallow a small capsule attached to a thin thread. Once it reaches the stomach, the capsule dissolves over approximately seven minutes, releasing a small sponge.

A trained healthcare professional then gently withdraws the sponge through the mouth, collecting cells from the oesophageal lining. The samples are sent to a laboratory to identify changes associated with Barrett’s oesophagus or cancer.

Approximately 95% of patients can swallow the capsule successfully, and the procedure generally requires only one specially trained healthcare professional.

By comparison, conventional endoscopy involves passing a flexible tube containing a camera down the throat and typically requires an endoscopist and at least two nurses.

The sponge procedure may cause temporary discomfort during removal, followed by a sore throat or mild irritation. Serious complications are uncommon.

Patients with abnormal findings still require endoscopy to confirm the diagnosis and determine whether further treatment is necessary.

The sponge test does not replace endoscopy for patients with suspected cancer. It provides an initial assessment to identify those who need more detailed examination.

NICE also cautions that neither capsule sponge testing nor endoscopy detects every case. Patients receiving negative results may still require long-term monitoring, depending on their clinical circumstances.

Barrett’s oesophagus and cancer risks linked to acid reflux

Barrett’s oesophagus develops when prolonged exposure to stomach acid changes the cells lining the lower oesophagus.

The condition affects approximately 1-2% of adults. Although most patients never develop cancer, Barrett’s oesophagus increases the long-term risk of oesophageal adenocarcinoma.

Persistent acid reflux is one of the main factors associated with the condition.

Reflux occurs when stomach contents flow back into the oesophagus, often because the sphincter separating the stomach and food pipe does not close effectively.

Symptoms can include heartburn, a burning sensation in the chest and an unpleasant acidic taste in the mouth.

An estimated 20% of people experience reflux symptoms at least once a week, while approximately 10% report symptoms every day.

Being overweight, smoking and alcohol consumption can increase the likelihood of reflux. Heartburn affects up to one in four UK adults.

The NICE recommendations focus on people with persistent reflux and multiple additional risk factors who do not require urgent referral for suspected cancer.

Patients already diagnosed with Barrett’s oesophagus may also be eligible for capsule sponge testing as part of ongoing surveillance.

Most people with Barrett’s oesophagus will not develop oesophageal cancer, but regular monitoring can identify cellular changes that require further investigation or treatment.

If precancerous abnormalities are detected, patients may undergo endoscopic treatment or radiofrequency ablation to remove or destroy affected tissue.

NHS aims to reduce endoscopy demand through community testing

The proposed guidance addresses growing demand for endoscopy services across NHS England.

Some patients with Barrett’s oesophagus are not receiving surveillance examinations as frequently as recommended because of limited endoscopy capacity.

Capsule sponge testing could allow healthcare providers to assess more patients in community settings while reserving hospital endoscopy for those with suspicious findings or other clinical indications.

Many patients prefer the sponge procedure because it is quicker, less invasive and avoids some of the risks associated with endoscopy.

The proposed testing pathway could reduce unnecessary endoscopies while directing specialist diagnostic resources towards patients with a greater likelihood of clinically significant disease.

Thousands of patients have already undergone capsule sponge testing through NHS pilot programmes.

The new recommendations are the first developed under the National HealthTech Access Programme, which aims to make effective medical technologies consistently available across England.

The consultation runs until December 7, 2026, with final NICE guidance expected in February 2027.

If the recommendations are confirmed, NHS England will be required to begin introducing the technology into the relevant clinical pathway, including training specialist staff.

Implementation would apply to eligible patients where capsule sponge testing is considered the most suitable diagnostic option.

Cancer sponge test expands into UK pharmacies

Alongside the national guidance proposals, a pharmacy-based testing pilot is expanding in north central London and the East Midlands.

Further participating pharmacies are planned in Barnet, Haringey and Islington in January 2027.

Currently, 21 pharmacies in north central London participate in the programme, including a Boots branch. Another six pharmacies are involved in the East Midlands.

The pilot, announced in July 2025, uses the EndoSign capsule sponge test to screen eligible patients for biological changes associated with Barrett’s oesophagus and oesophageal cancer.

The pharmacy programme has tested 268 patients and aims to reach 1,360 participants before its final evaluation in December 2027.

The initiative is part of the NHS Cancer Programme and primarily targets people over 45 with persistent heartburn or acid reflux.

By delivering tests outside hospitals, the programme aims to make diagnostic services more accessible and reduce pressure on specialist facilities.

Initial results from five East Midlands pharmacies showed that 79 patients had undergone testing by August 2026, with 25 referred for further care.

A sixth pharmacy, a Boots branch in Newark, joined the programme on November 6. In north central London, a Boots pharmacy in Wood Green and seven community pharmacies joined in July, followed by another 13 pharmacies in October.

Among the first 79 patients tested in the East Midlands pilot, 25 were referred for additional assessment, demonstrating how pharmacy testing can identify patients who may require further investigation.

The programme is scheduled to stop recruiting additional pharmacies on June 30, 2027. Its final evaluation report is expected by December 31, 2027.

NICE decision expected in February 2027

The proposed national rollout would extend the availability of Cytosponge and EndoSign beyond selected pilot locations.

NICE is assessing the technologies for patients with persistent reflux and elevated risk factors, as well as people requiring surveillance for previously diagnosed Barrett’s oesophagus.

The recommendation does not mean everyone experiencing occasional heartburn would automatically qualify for testing.

Eligibility would depend on symptoms, individual risk factors and clinical assessment. A negative sponge test does not completely exclude Barrett’s oesophagus or cancer, and patients may still need follow-up investigations or surveillance.

If NICE confirms its guidance in February 2027, NHS England will begin implementing the tests for eligible patients, supported by workforce training and integration into existing diagnostic pathways.

The wider pharmacy pilot will continue through 2027, providing further evidence on the practicality of delivering oesophageal cancer screening and Barrett’s oesophagus checks outside hospital settings.